De novo inhibitors occurring in previously treated patients who switched FVIII product in the frame of the Canadian surveillance system
| Giles et al49 . | Rubinger et al50 . |
|---|---|
| 339 inhibitor-free patients | 185 inhibitor-free patients |
| All switched from plasma-derived to a recombinant FVIII product | All switched from a recombinant FVIII to another second-generation recombinant FVIII |
| Central testing every 12 mo | Central testing every 12 mo |
| 2 y of follow-up | 2 y of follow-up |
| Inhibitor incidence: 14.7 per 1000 person-years | No de novo inhibitor |
| Giles et al49 . | Rubinger et al50 . |
|---|---|
| 339 inhibitor-free patients | 185 inhibitor-free patients |
| All switched from plasma-derived to a recombinant FVIII product | All switched from a recombinant FVIII to another second-generation recombinant FVIII |
| Central testing every 12 mo | Central testing every 12 mo |
| 2 y of follow-up | 2 y of follow-up |
| Inhibitor incidence: 14.7 per 1000 person-years | No de novo inhibitor |